Conclusions
Single agent carboplatin or CAP are as effective as carboplatin plus paclitaxel in the treatment of ovarian cancer.
The better side-effect profile of carboplatin alone makes it a reasonable first-line chemotherapeutic agent for ovarian cancer.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.